Supplemental Figure 1 from Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma

Examples of metabolic responders to GDC-0084 as indicated by a decrease in 18F-FDG PET uptake. A-B) Examples of a clear reduction in focal 18F-FDG uptake within the tumor. C-E) Example of more subtle reduction in 18F-FDG uptake after GDC-0084. C and E) demonstrate both focal (tumor) and global (gray matter) reductions in 18F-FDG uptake.